Nivedita Mahidhara
Internal Medicine · Aurora, CONPI 1124030432
Payments from drug & device makers
Across 112 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$318
- Amgen$280
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$228
- Lilly USA, LLC$203
- Novo Nordisk$181
- Pfizer$166
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,388100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $318 |
| Amgen | 13 | $280 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $228 |
| Lilly USA, LLC | 10 | $203 |
| Novo Nordisk | 9 | $181 |
| Pfizer | 7 | $166 |
| Idorsia Pharmaceuticals US Inc | 8 | $152 |
| Astellas Pharma US Inc | 5 | $134 |
| GSK | 5 | $103 |
| Merck | 5 | $93 |
| AbbVie | 3 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $88 |
| Johnson & Johnson | 4 | $77 |
| Sumitomo Pharma America, Inc. | 3 | $72 |
| Novartis | 3 | $60 |
| Esperion Therapeutics, Inc. | 3 | $58 |
| Boehringer Ingelheim | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| Heartflow, Inc. | 1 | $14 |
How this compares
$2,388 in reported general payments places this provider in the 90th percentile of 1,430 internal medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 16 | $7,015 |
| Atorvastatin Calcium | 45 | $591 |
| Levothyroxine Sodium | 23 | $323 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $262 |
| Olmesartan Medoxomil | 13 | $214 |
| Rosuvastatin Calcium | 25 | $173 |
| Gabapentin | 19 | $154 |
| Tamsulosin Hcl | 11 | $125 |
| Trazodone Hcl | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $93 | $7,01516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Aurora
- Alexis LealAurora$2M
- Mauricio WaintrubAurora$1.3M
- Kristine KuhnAurora$400K
- Kelsey FlintAurora$244K
- Paul Menard-KatcherAurora$203K
- Robert DoolanAurora$143K
- Cherry DelosreyesAurora$15K
- Shabana JiwaniAurora$10K
- Shahzaib NabiAurora$10K
- Stanton ElziWheat Ridge$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.